NCT04418297View on ClinicalTrials.gov

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 23, 2020

Primary Completion Date

November 22, 2022

Study Completion Date

November 22, 2022

Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
DRUG

CT-G20

oral tablet

DRUG

Placebo

oral tablet

Trial Locations (11)

10016

New York University Langone Medical Center, New York

13620

Seoul National University Bundang Hospital, Seongnam-si

61469

Chonnam National University Hospital, Gwangju

90048

Cedars-Sinai Medical Center, Los Angeles

02111

Tufts Medical Center, Boston

02097

Independent Public Central Clinical Hospital, Warsaw

04628

Institute of Cardiology in Warsaw, Warsaw

03080

Seoul National University Hospital, Seoul

03722

Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

06973

Chung-Ang University Hospital, Seoul

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT04418297 - A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter